1. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314
2. Nash RA, Antin JH, Karanes C et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 1997 90: 561a (Abstr. 2499)
3. Hiraoka AF for the Japanese FK506 BMT Study Group . Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporine in allogeneic bone marrow transplantation Blood 1997 90: 561a (Abstr. 2500)
4. Przepiorka D, Devine SM, Fay JW et al. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation Bone Marrow Transplant 1999 24: 1053–1056
5. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation Bone Marrow Transplant 1995 15: 895–899